Hemodynamic Effects of Spironolactone in Patients With Heart Failure

Not Applicable

Completed

• Conditions: Congestive Heart Failure
• Interventions: Drug: Spironolactone

• Registration Number: NCT00860340
• Lead Sponsor: University of Toledo Health Science Campus

Brief Summary

To determine if the beneficial effect of spironolactone in patients with congestive heart failure is in part due to its intrinsic inotropic action.

Randomized, two group placebo controlled, single blind study.

Detailed Description

Not available

Study Timeline

• Study Start: 2003-02
• Primary Completion: 2006-10
• Study Completion: 2006-10
• Study First Submitted: 2009-03-11
• Study First Submitted QC: 2009-03-11
• Study First Posted: 2009-03-12
• Status Verified: 2014-12
• Last Update Submitted: 2014-12-09
• Last Update Posted: 2014-12-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 18

Inclusion Criteria

• CHF
• 21 - 80 years
• Serum creatinine < 2 mg/dL
• Serum potassium 2.7 - 4.5 mg/dL measured within past 4 weeks

Exclusion Criteria

• Less than 21 years
• Pregnancy

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
1	Spironolactone	Study patient will take 100mg tablet of Spironolactone

Primary Outcome Measures

Name	Time	Method
Echocardiogram	3 measurements 15 minutes apart before drug and 15 minutes for 2 hours after drug
Measure of Kidney function and potassium levels	This will be taken before drug, two hours after and the following day

Trial Locations

Locations (1)

Medical University of Ohio; 🇺🇸 Toledo, Ohio, United States